Pathogenesis of drug-induced exanthems

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 57, Issue 10, 2002, Pages 884-893

  Pichler, W ^a,b   Yawalkar, N ^a   Schmid, S ^a   Helbling, A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN;

CELL FUNCTION; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOHISTOCHEMISTRY; PATCH TEST; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RASH; REVIEW; SKIN TEST; T LYMPHOCYTE;

ANIMALS; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; EXANTHEMA; HUMANS; T-LYMPHOCYTES;

EID: 0036786906     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2002.02161.x     Document Type: Review

References (65)

1. HUNZIKER T, KUNZI UP, BRAUNSCHWEIG S, ZEHNDER D, HOIGNÉ R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997;52:388-393.
2. LAZAROU J, POMERANZ BH, COREY PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1204.
3. PICHLER WJ, SCHNYDER B, ZANNI M, HARI Y, VON GREYERZ S. Role of T-cells in drug allergies. Allergy 1998;53:225-232.
4. HERTL M, MERK HF. Lymphocyte activation in cutaneous drug reactions. J Invest Dermatol 1995;105:95-98.
5. HARI Y, FRUTIG K, HURNI M, et al. T-cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001;31:1398-1408.
6. HERTL M, JUGERT F, MERK HF. CD8 + dermal T-cells from a sulphamethoxazole-induced bullous exanthema proliferate in response to drug-modified liver microsomes. Br J Dermatol 1995;132:215-220.
7. ZANNI MP, MAURI-HELLWEG D, BRANDER C et al. Characterization of lidocaine-specific T-cells. J Immunol 1997;158:1139-1148.
8. BRITSCHGI M, STEINER U, SCHMID S, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001;11:1433-1441.
9. TSUTSUI H, TERANO Y, SAKAGAMI C, HASEGAWA I, MIZOGUCHI Y, MORISAWA S. Drug-specific T-cells derived from patients with drug-induced allergic hepatitis. J Immunol 1992;149:706-716.
10. SCHNYDER B, FRUTIG K, MAURI-HELLWEG D et al. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 1998;28:1412-1417.
11. HERTL M, GEISEL J, BOECKER C, MERK HF. Selective generation of CD8 + T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics. Br J Dermatol 1993;128:619-626.
12. POSADAS SJ, LEYVA L, TORRES MJ et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J Allergy Clin Immunol 2000;106:769-776.
13. BRANDER C, MAURI-HELLWEG D, BETTENS F et al. Heterogeneous T-cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. J Immunol 1995;55:2670-2678.
14. KALISH RS, ASKENASE PW. Molecular mechanisms of CD8 + T-cell-mediated delayed hypersensitivity: implications for allergies, asthma and autoimmunity. J Allergy Clin Immunol 1999;103:192-199.
15. SCHNYDER B, MAURI-HELLWEG D, ZANNI M et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human T-cell clones. J Clin Invest 1997;100:136-141.
16. WELTZIEN HU, MOULIN C, MARTIN S, PADOVAN E, HARTMANN U, KOHLER J. T-cell immune response to haptens: Structural models for allergic and autoimmune reactions. Toxicology 1996;107:141-151.
17. GRIEM P, WULFERINK M, SACHS B, GONZALEZ JB, GLEICHMANN E. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 1998;19:133-141.
18. PICHLER WJ. Pharmacological interaction of drugs with antigen-specific immune receptors. Current Opinion Allergy Clin Immunol 2002 (in press).
19. GALLUCCI S, MATZINGER P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001;13:114-119.
20. NAISBITT DJ, GORDON SF, PIRMOHAMED M, PARK BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Safety 2000;23:483-507.
21. HELLER HM. Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infection. Clin Dermatol 2000;18:485-489.
22. SUZUKI Y, INAGE R, AONO T, YAMANISHI K, SHIOHARA T. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermotol 1996;134:1108-1112.
23. ANTONEN JA, MARKULA KP, PERTOVAARA MI, PASTERNACK AI. Adverse drug reactions in Sjögren syndrome. Frequent allergic reactions and a specific trimethoprim-associated systemic reaction. Scand J Rheumatol 1999;28:157-159.
24. PICHLER WJ. Predictive drug allergy testing, an alternative viewpoint. Toxicology 2001;158:31-41.
25. PICHLER WJ, YAWALKAR N, BRITSCHEIM et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002;3:229-238.
26. CROWSON AN, MAGRO CM. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin 1999;17:537-560.
27. FELLNER MJ, PRUTKIN L. Morbilliform eruptions caused by penicillin. A study by electron microscopy and immunologic tests. J Invest Dermatol 1970;55:390-395.
28. YAWALKAR N, SHRIKHANDE M, HARI Y et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000;106:1171-1176.
29. YAWALKAR N, EGLI F, HARI Y et al. Infiltration of cytotoxic T-cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000;30:847-855.
30. BARBAUD AM, BENE MC, REICHERT-PENETRAT S et al. Immunocompetent T-cells and adhesion molecules in 14 cases of cutaneous drug reactions induced with the use of antibiotics. Arch Dermatol 1998;134:1040-1041.
31. BARBAUD AM, BENE MC, SCHMUTZ JL et al. Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes. Arch Dermatol 1997;133:481-486.
32. BLANCA M, POSADAS S, TORRES MJ et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with non immediate cutaneous allergic drug reactions. Allergy 2000;55:998-1004.
33. STEPP SE, MATHEW PA, BENNETT M et al. Perforin: more than just an effector molecule. Immunol Today 2000;21:254-256.
34. BEHRENDT C, GOLLNICK H, BONNEKOH B. Up-regulated perforin expression of CD8 + blood lymphocytes in generalized non-anaphylactic drug eruptions and exacerbated psoriasis. Eur J Dermatol 2000;10:365-369.
35. YAWALKAR N, HARI Y, FRUTIG K et al. T-cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000;115:647-652.
36. POSADAS SJ, PADIAL A, TORRES MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002;109:155-161.
37. VIARD I, WEHRLI P, BULLANI R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-493.
38. LE CLEACH L, DELAAIRE S, BOUMSELL L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000;119:225-230.
39. NASSIF A, BENSUSSAN A, DOROTHÉE G, et al. Drug-specific cytotoxic T lymphocytes in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002;118:728-733.
40. BRUGNOLO F, ANNUNZIATO F, SAMPOGNARO S, et al. Highly Th2-skewed cytokine profile of beta-lactam-specific T-cells from nonatopic subjects with adverse drug reactions. J Immunol 1999;163:1053-1059.
41. HARI Y, URWYLER A, HURNI M, et al. Distinct serum cytokine levels in drug or measles induced exanthema. Int Arch Allergy Immunol 1999;120:225-229.
42. CHOQUET-KASTYLEVSKY G, INTRATOR L, CHENAL C, BOCQUET H, REVUZ J, ROUJEAU JC. Increased levels of Interleukin 5 are associated with the generation of eosinophilia in drug -induced hypersensitivity syndrome. Br J Dermatol 1998;139:1026-1032.
43. PICHLER WJ, ZANNI M, VON GREYERZ S, SCHNYDER B, MAURI-HELLWEG D, WENDLAND T. High IL-5 production by drug specific T-cell clones. Int Arch Appl All Immunol 1997;113:177-180.
44. GERBER BO, ZANNI MP, UGUCCIONI M, et al. Functional expression of the eotaxin receptor, CCR3, in T lymphocytes co-localizing with eosinophils. Current Biol 1997;7:836-843.
45. BEYLOT C, BIOULAC P, DOUTRE MS. Poustuloses exanthématiques aïgues généralisées. A propos de 4 cas. Ann Dermatol Venerol 1980;107:37-48.
46. ROUJEAU J, BIOULAC-SAGE P, BOURSEAU C. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991;127:1333-1338.
47. WOLKENSTEIN P, CHOSIDOW O, FLÉCHET ML et al. Patch-testing in severe cutaneous adverse drug reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996;35:234-236.
48. COOMBS PRA, GELL PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: RRA GELL, editor. Clinical Aspects of Immunology. Oxford, UK: Oxford University Press 1968, 575-596.
49. JANEWAY CA, TRAVERS P, WALPORT M, SHLOCHIK M. Immunobiology. London: Garland Publishing 2001.
50. CALKIN JM, MAIBACH HI. Delayed hypersensitivity drug reactions diagnosed by patch testing. Contact Dermatitis 1993;29:223-233.
51. BRUYNZEEL DP, MAIBACH HI. Patch testing in systemic drug eruptions. Clinics Dermatol 1997;15:47.
52. ROMANO A, QUARANTINO D, DI FONSO M, PAPA G, VENUTI A, GASBARRINI G. A diagnostic protocol for evaluating non-immediate reactions to aminopenicllins. J Allergy Clin Immunol 1999;103:1186-1190.
53. TORRES MJ, ROMANO A, MAYORGA C, et al. Diagnostic evaluation of a large group of patients with immediate allergy to penicillins: the role of skin testing. Allergy 2001;56:850-856.
54. YAWALKAR N, HARI Y, FRUTIG K, et al. T-cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug-specific and cytotoxic. J Invest Dermatol 2000;115:647-652.
55. BARBAUD A, REICHERT-PENETRAT S, TRECHOT P, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998;139:49-58.
56. NEUKOMM C, YAWALKAR N, HELBLING A, PICHLER WJ. T-cell reactions to drugs in distinct clinical manifestations of drug allergy. J Invest Allerg Clin Immunol 2001;11:275-284.
57. NYFELER B, PICHLER WJ. Sensitivity and specificity of the lymphocyte transformation test to drugs. Clin Exp Allergy 1997;27:175-181.
58. MAURI-HELLWEG D, BETTENS F, MAURI D, BRANDER C, HUNZIKER T, PICHLER WJ. Activation of drug-specific CD4 + and CD8 + T-cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J Immunol 1995;155:462-472.
59. SCHAUB N, BIRCHER AJ. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000;55:191-193.
60. SCHNYDER B, PICHLER WJ. Diagnostic tests in amoxicillin and penicillin induced morbilliform skin eruption. Clin Exp Allergy 2000;30:590-595.
61. LUQUE I, LEYVA L, JOSE TORRES M, et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 2001;56:611-618.
62. JOH K, AIZAWA S, YAMAGUCHI Y, et al. Drug-induced hypersensitivity nephritis: lymphocyte stimulation testing and renal biopsy in 10 cases. Am J Nephrol 1990;10:222-230.
63. ROUJEAU JC, ALBENGRES E, MORITZ S, et al. Lymphocyte transformation test in drug-induced toxic epidermal necrolysis. Int Arch Allergy Appl Immunol 1985;78:22-24.
64. SACHS B, ERDMANN S, AL-MASAOUDI T, MERK HF. In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol 2001;144:316-320.
65. JOHANSSON SGO, O'B HOURIHANE J, BOUSQUET J, et al. A revised nomenclature for allergy. Allergy 2001;56:813-824.